Supplementary Table 1. Baseline clinical characteristics and pathologic outcomes. All men were NCCN very low risk, had extended biopsy sampling (≥10 cores), and were treated in the modern Gleason grading era (≥2004)

	Caucasian, n=89	African American, n=87	*p*
(a) PRE-OPERATIVE CHARACTERISTICS			
Mean Age (Years)	57.3	58.2	0.240
Median PSA (ng/ml) (IQR)	4.4 (3.3, 5.3)	4.5 (3.5, 5.7)	0.371*
Median Prostate size (g) (IQR)	48.5 (41.0, 55.9)	49.7 (40.0, 65.4)	0.331*
Median PSA density (ng/ml/g) (IQR)	0.09 (0.07, 0.12)	0.09 (0.06, 0.11)	0.746*
Number of positive cores 1 2	 53 (59.6%) 36 (40.5%)	 48 (55.2%) 39 (44.8%)	0.557
Median % ca. per core (IQR)	10.0 (5.0, 30.0)	10.0 (5.0, 30.0)	0.450*
CAPRA 0-1 2-3	 76 (85.4%) 13 (14.6%)	 68 (78.2%) 19 (21.8%)	0.214
Family history	41 (46.1%)	36 (41.4%)	0.487
Median BMI kg/m^2 (IQR)	27.2 (25.1, 29.7)	27.5 (25.8, 30.1)	0.399*
Charlson index 0 1 2 or 3	 25/28 (89.3%) 3/28 (10.7%) 0/28 (0.0%)	 18/29 (62.1%) 10/29 (34.5%) 1/29 (3.5%)	**0.041**[†]
(b) PATHOLOGIC CHARACTERISTICS			
Pathologic stage pT0 pT2N0 pT3aN0	 2 (2.3%) 83 (93.3%) 3 (3.4%)	 2 (2.3%) 72 (82.8%) 13 (14.9%)	**0.008**
Path Gleason ≤6 7 (3+4) 7 (4+3) 8 (3+5) 8 (4+4) 9 (4+5)	 79 (88.8%) 8 (9.0%) 1 (1.1%) 0 (0%) 1 (1.1%) 0 (0%)	 55 (63.2%) 27 (31.0%) 2 (2.3%) 1 (1.1%) 1 (1.1%) 1 (1.1%)	**0.001**
Upgrade	10 (11.2%)	32 (36.8%)	**<0.001**
PSM	5 (5.6%)	17 (19.8%)	**0.002**
Adverse pathology**	5 (5.6%)	16 (18.4%)	**0.009**
CAPRA-S 0-2 3-5	 87 (97.8%) 2 (2.2%)	 69 (79.3%) 18 (20.7%)	**<0.001**

*p-value derived from Wilcoxon-Mann-Whitney test, IQR=interquartile range

[†]p-value derived from Fisher's exact test

**Adverse pathologic findings: pT2 and ≥G4+3 OR pT3a and G3+3 and PSM OR pT3a and ≥G3+4 OR ≥pT3b